DURECT Corporation (DRRX)
USD 0.8
(0.01%)
USD 0.8
(0.01%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 45.18 Million USD | -24.81% |
| 2022 | 60.1 Million USD | -34.67% |
| 2021 | 91.99 Million USD | 21.61% |
| 2020 | 75.64 Million USD | -12.07% |
| 2019 | 86.02 Million USD | 72.04% |
| 2018 | 49.99 Million USD | -5.86% |
| 2017 | 53.11 Million USD | 31.12% |
| 2016 | 40.5 Million USD | -13.39% |
| 2015 | 46.77 Million USD | -6.61% |
| 2014 | 50.08 Million USD | 22.69% |
| 2013 | 40.82 Million USD | -11.14% |
| 2012 | 45.93 Million USD | -6.63% |
| 2011 | 49.19 Million USD | -27.18% |
| 2010 | 67.56 Million USD | 16.18% |
| 2009 | 58.15 Million USD | -22.33% |
| 2008 | 74.87 Million USD | -10.89% |
| 2007 | 84.02 Million USD | -18.02% |
| 2006 | 102.48 Million USD | -12.71% |
| 2005 | 117.41 Million USD | 37.38% |
| 2004 | 85.46 Million USD | -23.97% |
| 2003 | 112.4 Million USD | 54.04% |
| 2002 | 72.97 Million USD | -30.47% |
| 2001 | 104.94 Million USD | -12.99% |
| 2000 | 120.61 Million USD | 436.94% |
| 1999 | 22.46 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 29.85 Million USD | -17.58% |
| 2024 Q1 | 36.22 Million USD | -19.85% |
| 2023 Q2 | 48.65 Million USD | -16.61% |
| 2023 Q1 | 58.34 Million USD | -2.91% |
| 2023 Q4 | 45.18 Million USD | -17.43% |
| 2023 FY | 45.18 Million USD | -24.81% |
| 2023 Q3 | 54.72 Million USD | 12.48% |
| 2022 FY | 60.1 Million USD | -34.67% |
| 2022 Q1 | 80.53 Million USD | -12.46% |
| 2022 Q3 | 68.47 Million USD | -2.15% |
| 2022 Q2 | 69.97 Million USD | -13.1% |
| 2022 Q4 | 60.1 Million USD | -12.23% |
| 2021 Q1 | 116.05 Million USD | 53.43% |
| 2021 FY | 91.99 Million USD | 21.61% |
| 2021 Q4 | 91.99 Million USD | -6.1% |
| 2021 Q2 | 106.26 Million USD | -8.43% |
| 2021 Q3 | 97.96 Million USD | -7.82% |
| 2020 Q3 | 70.15 Million USD | -3.58% |
| 2020 Q1 | 74.12 Million USD | -13.83% |
| 2020 FY | 75.64 Million USD | -12.07% |
| 2020 Q4 | 75.64 Million USD | 7.82% |
| 2020 Q2 | 72.76 Million USD | -1.83% |
| 2019 Q4 | 86.02 Million USD | -2.53% |
| 2019 Q2 | 59.98 Million USD | 15.93% |
| 2019 Q1 | 51.74 Million USD | 3.49% |
| 2019 Q3 | 88.25 Million USD | 47.13% |
| 2019 FY | 86.02 Million USD | 72.04% |
| 2018 Q3 | 56.86 Million USD | -0.94% |
| 2018 FY | 49.99 Million USD | -5.86% |
| 2018 Q1 | 59.67 Million USD | 12.36% |
| 2018 Q2 | 57.39 Million USD | -3.82% |
| 2018 Q4 | 49.99 Million USD | -12.07% |
| 2017 Q2 | 49.93 Million USD | 50.87% |
| 2017 Q1 | 33.09 Million USD | -18.3% |
| 2017 FY | 53.11 Million USD | 31.12% |
| 2017 Q3 | 57.75 Million USD | 15.66% |
| 2017 Q4 | 53.11 Million USD | -8.04% |
| 2016 Q3 | 43.57 Million USD | -13.7% |
| 2016 Q1 | 41.19 Million USD | -11.92% |
| 2016 Q2 | 50.49 Million USD | 22.55% |
| 2016 Q4 | 40.5 Million USD | -7.04% |
| 2016 FY | 40.5 Million USD | -13.39% |
| 2015 Q3 | 48.31 Million USD | -8.97% |
| 2015 Q4 | 46.77 Million USD | -3.19% |
| 2015 FY | 46.77 Million USD | -6.61% |
| 2015 Q1 | 45.51 Million USD | -9.12% |
| 2015 Q2 | 53.07 Million USD | 16.6% |
| 2014 Q1 | 37.98 Million USD | -6.94% |
| 2014 Q2 | 53.43 Million USD | 40.67% |
| 2014 FY | 50.08 Million USD | 22.69% |
| 2014 Q3 | 52.9 Million USD | -1.0% |
| 2014 Q4 | 50.08 Million USD | -5.33% |
| 2013 FY | 40.82 Million USD | -11.14% |
| 2013 Q4 | 40.82 Million USD | 26.68% |
| 2013 Q3 | 32.22 Million USD | -12.05% |
| 2013 Q1 | 40.9 Million USD | -10.94% |
| 2013 Q2 | 36.64 Million USD | -10.43% |
| 2012 Q1 | 43.7 Million USD | -11.17% |
| 2012 Q2 | 40.23 Million USD | -7.95% |
| 2012 FY | 45.93 Million USD | -6.63% |
| 2012 Q4 | 45.93 Million USD | 25.46% |
| 2012 Q3 | 36.61 Million USD | -8.99% |
| 2011 Q3 | 53.24 Million USD | -2.01% |
| 2011 FY | 49.19 Million USD | -27.18% |
| 2011 Q4 | 49.19 Million USD | -7.61% |
| 2011 Q2 | 54.34 Million USD | -9.34% |
| 2011 Q1 | 59.94 Million USD | -11.27% |
| 2010 Q3 | 69.82 Million USD | -6.32% |
| 2010 FY | 67.56 Million USD | 16.18% |
| 2010 Q2 | 74.53 Million USD | 38.67% |
| 2010 Q4 | 67.56 Million USD | -3.24% |
| 2010 Q1 | 53.75 Million USD | -7.57% |
| 2009 Q4 | 58.15 Million USD | -11.17% |
| 2009 FY | 58.15 Million USD | -22.33% |
| 2009 Q1 | 68.4 Million USD | -8.64% |
| 2009 Q2 | 61.82 Million USD | -9.62% |
| 2009 Q3 | 65.46 Million USD | 5.89% |
| 2008 Q1 | 75.27 Million USD | -10.41% |
| 2008 Q3 | 60.23 Million USD | -12.56% |
| 2008 Q2 | 68.88 Million USD | -8.49% |
| 2008 FY | 74.87 Million USD | -10.89% |
| 2008 Q4 | 74.87 Million USD | 24.31% |
| 2007 Q2 | 96.55 Million USD | 1.12% |
| 2007 FY | 84.02 Million USD | -18.02% |
| 2007 Q4 | 84.02 Million USD | -7.41% |
| 2007 Q1 | 95.48 Million USD | -6.83% |
| 2007 Q3 | 90.74 Million USD | -6.02% |
| 2006 Q4 | 102.48 Million USD | 6.09% |
| 2006 Q3 | 96.6 Million USD | -5.46% |
| 2006 Q2 | 102.18 Million USD | -8.01% |
| 2006 Q1 | 111.07 Million USD | -5.4% |
| 2006 FY | 102.48 Million USD | -12.71% |
| 2005 Q2 | 86.85 Million USD | -4.13% |
| 2005 Q3 | 85.54 Million USD | -1.51% |
| 2005 Q4 | 117.41 Million USD | 37.26% |
| 2005 FY | 117.41 Million USD | 37.38% |
| 2005 Q1 | 90.6 Million USD | 6.01% |
| 2004 Q3 | 93.39 Million USD | -6.0% |
| 2004 Q4 | 85.46 Million USD | -8.48% |
| 2004 FY | 85.46 Million USD | -23.97% |
| 2004 Q1 | 107.25 Million USD | -4.59% |
| 2004 Q2 | 99.35 Million USD | -7.37% |
| 2003 Q1 | 67.22 Million USD | -7.87% |
| 2003 FY | 112.4 Million USD | 54.04% |
| 2003 Q2 | 112.53 Million USD | 67.4% |
| 2003 Q3 | 119.11 Million USD | 5.85% |
| 2003 Q4 | 112.4 Million USD | -5.63% |
| 2002 Q3 | 77.35 Million USD | -9.23% |
| 2002 Q4 | 72.97 Million USD | -5.66% |
| 2002 Q1 | 95.05 Million USD | -9.43% |
| 2002 Q2 | 85.21 Million USD | -10.34% |
| 2002 FY | 72.97 Million USD | -30.47% |
| 2001 FY | 104.94 Million USD | -12.99% |
| 2001 Q4 | 104.94 Million USD | -8.96% |
| 2001 Q3 | 115.27 Million USD | -5.28% |
| 2001 Q2 | 121.69 Million USD | 3.29% |
| 2001 Q1 | 117.82 Million USD | -2.31% |
| 2000 FY | 120.61 Million USD | 436.94% |
| 2000 Q3 | 116.13 Million USD | 160.02% |
| 2000 Q4 | 120.61 Million USD | 3.85% |
| 2000 Q2 | 44.66 Million USD | 0.0% |
| 1999 FY | 22.46 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Journey Medical Corporation | 76.84 Million USD | 41.198% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 95.004% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 21.298% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 97.13% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -65.243% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -65.243% |
| SCYNEXIS, Inc. | 128.41 Million USD | 64.809% |
| Safety Shot Inc | 12.7 Million USD | -255.562% |
| Alpha Teknova, Inc. | 128.58 Million USD | 64.857% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 96.048% |
| Bright Green Corporation | 17.4 Million USD | -159.661% |
| Dynavax Technologies Corporation | 997.09 Million USD | 95.468% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 78.042% |
| Cosmos Health Inc. | 66.29 Million USD | 31.837% |
| PainReform Ltd. | 9.93 Million USD | -355.076% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -95.395% |
| Embecta Corp. | 1.21 Billion USD | 96.279% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 93.795% |
| Procaps Group, S.A. | 460.18 Million USD | 90.18% |
| Theratechnologies Inc. | 77.76 Million USD | 41.893% |
| Harrow Health, Inc. | 311.75 Million USD | 85.505% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -203.424% |
| Biofrontera Inc. | 27.93 Million USD | -61.782% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 96.793% |
| Cronos Group Inc. | 1.13 Billion USD | 96.016% |
| OptiNose, Inc. | 107.72 Million USD | 58.053% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 90.407% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 19.232% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -96.072% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 90.177% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -279.16% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 44.741% |
| Radius Health, Inc. | 1.71 Billion USD | 97.367% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 15.197% |
| ProPhase Labs, Inc. | 91.92 Million USD | 50.843% |
| Phibro Animal Health Corporation | 982.18 Million USD | 95.399% |
| Procaps Group S.A. | 460.18 Million USD | 90.18% |
| Alvotech | 950.09 Million USD | 95.244% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -4.341% |
| Viatris Inc. | 47.68 Billion USD | 99.905% |
| Rockwell Medical, Inc. | 52.17 Million USD | 13.386% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 61.735% |
| SIGA Technologies, Inc. | 254.83 Million USD | 82.267% |
| Tilray Brands, Inc. | 4.33 Billion USD | 98.958% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 83.49% |
| Shineco, Inc. | 84.17 Million USD | 46.318% |
| PetIQ, Inc. | 868.22 Million USD | 94.795% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -435.528% |
| Incannex Healthcare Limited | 17.04 Million USD | -165.085% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 98.61% |
| Alimera Sciences, Inc. | 153.52 Million USD | 70.566% |
| Silver Spike Investment Corp. | 88.57 Million USD | 48.983% |
| Assertio Holdings, Inc. | 286.41 Million USD | 84.223% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -659.257% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -33.712% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -44.637% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -241.112% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 82.695% |
| Hempacco Co., Inc. | 18.04 Million USD | -150.451% |
| Talphera, Inc. | 20.39 Million USD | -121.569% |
| Alvotech | 950.09 Million USD | 95.244% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 88.874% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 97.263% |
| Currenc Group, Inc. | 141.49 Million USD | 68.062% |
| Kamada Ltd. | 351.96 Million USD | 87.161% |
| Indivior PLC | 1.95 Billion USD | 97.684% |
| Evoke Pharma, Inc. | 7.06 Million USD | -539.297% |
| Flora Growth Corp. | 23.62 Million USD | -91.268% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -241.112% |
| Evolus, Inc. | 188.99 Million USD | 76.09% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 96.469% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 97.013% |
| Akanda Corp. | 8.83 Million USD | -411.188% |